| Clinical data | |
|---|---|
| Other names | FP-020 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C20H17N3O4S |
| Molar mass | 395.43 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Linvemastat is an investigational new drug that is being evaluated by Foresee Pharmaceuticals for the treatment of Asthma. It is a matrix metalloproteinase 12 inhibitor.